Pharmacodynamic Effects of Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion in Patients Undergoing Percutaneous Coronary Intervention
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2017
Price : $35 *
At a glance
- Drugs Ticagrelor (Primary) ; Eptifibatide
- Indications Acute coronary syndromes
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 31 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.